Cultivating Healthy Connections: Exploring and Engineering the Microbial Flow That Shapes Microbiomes

Travis J. Wiles

ABSTRACT  Our view of the microbial world has undergone a radical transformation over the past decade. For most of the 20th century, medical microbiological research was focused on understanding the virulent nature of disease-causing pathogens. More recently, advances in DNA sequencing methodologies have exposed a wider diversity of microscopic wildlife that associate with our bodies and the environments around us, and the unexpected roles they play in supporting our health. Our expanding view of the microbial world is now motivating therapeutic interventions that are based not just on the elimination of nefarious pathogens but the nurturing of beneficial microbiomes. In this Commentary, I consider how our historically pathogen-based view of host-microbe interactions may be limiting the scope of new and alternative strategies for engineering microbiomes. I suggest that recognizing the therapeutic potential of the ongoing microbial transmission that connects microbiomes could illuminate unexplored opportunities for cultivating healthy host-microbe relationships.

KEYWORDS  antibiotic resistance, beneficial microbes, host-microbe interactions, host-microbe systems biology, microbial ecology, microbial transmission, microbiome, microbiome engineering

OUR EXPANDING VIEW OF THE MICROBIAL WORLD

Over the last decade there has been a collective awakening across scientific disciplines and society to the multitudes of microorganisms that inhabit our bodies and the environments we occupy. Compelling discoveries of how indigenous microbes support our health and predispose us to disease are being made at a rapid clip. Our microbiome can facilitate the harvesting of nutrients and energy from our diet (1), protect us from pathogens (2), modulate our susceptibility to chronic and complex disorders like asthma (3) and autoimmune diabetes (4), and influence our likelihood of developing cancer (5) and whether we will respond to treatment (6). The mechanisms underlying our interactions with microbes and their potential to serve as therapeutic targets are starting to be clarified using experimental animal models such as mouse, zebrafish, and several invertebrate species (e.g., bobtail squid, fruit flies, and nematodes). It is incredible to think that obtaining a complete picture of human biology (and the biology of other animals) was likely never possible without considering the microscopic wildlife that surrounds us. Ultimately, the insights generated from modern microbiome research are catalyzing dramatic shifts in how we view and interact with the microbial world (7).

To appreciate how our relationship with the microbial world is changing, it is important to consider how it formed in the first place (7). The original microbial envoys were mostly pathogens (e.g., Vibrio cholerae, Bacillus anthracis, Yersinia pestis, and Mycobacterium tuberculosis), and since the widespread acceptance of the germ theory of disease over 120 years ago, pathogens have dominated our conceptual framework for understanding microbes. Pathogens decided the terms of our initial engagements and dictated the battlefield for our confrontations: our bodies.
In response, a tremendous amount of research throughout the 20th century was devoted to deciphering the genes and pathways that infectious microbes use to invade and replicate within our tissues and cells, and how these encounters lead to acute and life-threatening afflictions. As a result, we have developed countermeasures such as broad-spectrum antibiotics and vaccines to rid our bodies of unwanted microbial intruders. Our historically adversarial relationship with microbes now stands in sharp contrast to new microbiome-based therapies that are focused on treating disease by cultivating microbes, not by eradicating them. But as we strive to learn how to grow healthy microbiomes, it is also worth considering how our conflicts with pathogens have shaped our assumptions about host-microbe interactions and their underlying mechanisms.

It can be argued that pathogens have imprinted on us the expectation that for any given disease or health-promoting property of the microbiome, there should be a single prominent microbe—at a concurrent place and time—that is responsible. Accordingly, once we have identified a candidate microbe, therapeutic interventions are often designed to modify its presence or activity where health and disease most obviously manifest: within an individual host. This playbook for investigating host-microbe interactions has been successful and will undoubtedly continue to guide us. Indeed, specific microbial strains or lineages have been linked to microbiome activities such as educating the immune system (8), inhibiting pathogen colonization (2), and sparking inflammation (9). However, the default "one host, one microbe" view of host-microbe interactions may be restricting our field of vision. An expanded and more integrated view would superimpose our current working definitions of host-microbe interactions onto a broader ecological and systems-level framework that encompasses interacting networks of hosts, the environment, and the microbes that connect them. In this wider panorama, new and alternative therapeutic interventions come into focus. Rather than treating afflictions at the scale of a single host and microbe, interventions could be designed to canalize entire host-microbe systems in a way that channels health-promoting microbial factors or processes while diverting those that drive disease.

THE THERAPEUTIC POTENTIAL OF MICROBIOME CONNECTIVITY

Our personal microbiomes are often referred to as a "microbial organ" to emphasize the vital functions they provide us. Although this comparison is largely taken to be metaphorical, it does convey some truth. As with actual organs such as the heart or liver, microbiomes can be transplanted from one host to another. Experimentally, this attribute has been exploited to demonstrate the sufficiency of microbiome-encoded activities to modify or confer certain host phenotypes (e.g., inflammation [10]). Clinically, fecal microbiota transplants have been used in humans to repair damaged microbiomes after antibiotic treatment (11) and improve responsiveness to cancer immunotherapy (12). But, outside controlled experimental and clinical applications, a property of microbiomes that is not shared with real organs is that microbiome transmissibility is a natural and ongoing process (13, 14).

Signatures of microbial flux among humans, animals, and the environment continue to be detected by increasingly large-scale DNA sequencing-based microbiome projects. For example, taxa from a mother’s microbiome can be vertically transferred to her newborn child during birth (15), and there is evidence of microbiota transmission among cohabiting family members, housemates, and pets (16, 17). There are microbial exchanges between people and the built environment as well, which in some cases can occur on surprisingly rapid time scales. For example, hospital patients can start acquiring microbes from the rooms they occupy within the first 24 h of their stay (18). Likewise, hospital rooms accumulate microbial traces of the patients they house over time. But perhaps some of the most striking signatures of microbiome transmission come from studies charting the spread of antibiotic-resistant bacteria.

Antibiotic-resistant bacteria are an intensifying public health threat. The urgency of this problem has prompted the tracking of antibiotic-resistant bacteria and the
resistance genes they carry throughout the biosphere and across human and animal populations. Monitoring the movements of antibiotic-resistant bacteria is essential for preventing incurable infections and informing newly emerging “One Health” policies. However, an added benefit of this surveillance is that it helps define the possible routes and dynamics of microbial transmission that connect microbiomes.

Drug-resistant bacteria and resistance genes are alarmingly omnipresent. Reflecting this fact, a recent study of mass transit systems from 60 cities across the world revealed that antibiotic resistance genes are common in urban microbiomes (i.e., the microbial communities that live on the surfaces of urban built environments) (19). Notably, urban microbiomes appear to contain city-specific resistance gene fingerprints, highlighting a potential for globe-trotting humans to acquire and spread antibiotic-resistant bacteria. Demonstrating this potential, multiple studies have indicated that, on average, one-third of international travelers may acquire bacteria carrying genes that encode extended-spectrum beta-lactamases or resistance to last-resort antibiotics such as colistin and carbapenems (20, 21). In some regions of Asia and Africa acquisition rates were observed to be near or above 50%. It was further observed that travel-acquired drug-resistant bacteria could reside within an individual traveler’s microbiome for up to a year after returning home and, in some instances, could also be transmitted to another household member (20).

On a regional scale, the epidemiology of plasmid-based colistin resistance (specifically, mcr-1) signals the potential for transmission of drug-resistant bacteria through production animal supply chains. Unexpectedly high rates of mcr-1 carriage (15% on average) were recently detected in fecal samples of healthy human individuals across numerous provinces and municipalities in China (22). One of the strongest predictors of mcr-1 carriage is a high daily intake of aquatic food products. This link is notable because it has been proposed that agricultural runoff contaminated with colistin may have first stimulated the emergence and amplification of mcr genes in aquatic bacteria (23–25). In turn, it is thought that integrated aquaculture practices and consumption of aquaculture-derived food have led to the horizontal transfer of mcr genes to terrestrial and human-associated bacteria (24, 25).

Together, the examples above begin to outline a picture of microbial flow that connects human, animal, and environmental microbiomes (Fig. 1). With this picture in mind, it becomes difficult to ignore the potential for continuous microbial transmission to shape and reshape our microbiomes—which in turn could shape and reshape our biology. I specifically called attention to antibiotic resistance as a pronounced example of how microbial transmission and microbiome connectivity can underlie public and
individual health. But similar processes are likely at work for a range of microbiome-based diseases. For example, it is possible that chronic diseases that are typically thought of as noncommunicable and labeled as epidemic may be driven, in part, by actual epidemics of microbial spread. Conversely, it is tempting to speculate whether the individual microbes that comprise microbiomes come from? What controls whether they colonize and assemble into a community or disperse to new hosts and throughout the environment? How do the life history and evolution of microbes impact the form and function of microbiomes? Adding to the allure of exploring these questions is the prospect of resolving the interconnections among the multitude of nested life cycles within microbiomes—spanning hosts, bacteria, viruses, and mobile genetic elements. Ultimately, I think attaining a systems-level view of host-microbe interactions that captures the mechanisms driving microbial life cycles will inspire new therapeutic interventions that promote individual health by targeting and controlling microbiome connectivity.

ACKNOWLEDGMENTS

I thank Katrine Whitenet for nominating me to contribute this article and for the thoughtful and productive reviewer feedback. I also thank Tish Wiles and Maria Bahuelos for their time and suggestions and the rest of our lab (Nancy Haro-Ramirez, Calvin Trinh, Sakshi Chikkalgi, and Raghavi Misra) for their contributions to the launch of our lab over the past year. And I thank my former advisors Karen Guillemine and Matthew Mulvey for their mentorship, without which I would not be able to imagine the research questions I find so motivating.

Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award number DP2AI154420. The content is solely the responsibility of the author and does not necessarily represent the official views of the National Institutes of Health.

REFERENCES

1. Gehrig JL, Venkatesh S, Chang HW, Hibberd MC, Kung VL, Cheng J, Chen RY, Subramanian S, Cowardin CA, Meier MF, O’Donnell D, Talcott M, Spears LD, Semenkovich CF, Henriassit B, Giannone RJ, Hettich RL, Ikayoova O, Muehlbauer M, Newgard CB, Sawyer C, Head RD, Rodionov DA, Arzamassov AA, Leyn SA, Osterman AL, Hossain MI, Islam M, Choudhury N, Sarker SA, Hug S, Mahmoud I, Mostafa I, Mafuz M, Barratt MJ, Ahmed T, Gordon JI. 2019. Effects of microbiota-directed foods in gnotobiotic animals and undernourished children. Science 365:eaau4732. https://doi.org/10.1126/science.aau4732.
2. Buffie CG, Bucci V, Stein RR, McKinney PT, Ling L, Gobourne A, No D, Liu H, Kinnnebrew M, Viale A, Littmann E, Van Den Brink MIN, Jenq RR, Taur Y, Sander G, Cross JR, Toussaint NC, Xavier JB, Palmer EG. 2015. Precision microbiome restoration restores bile acid mediated resistance to Clostridium difficile. Nature 517:205–208. https://doi.org/10.1038/nature13828.
3. Stokholm J, Blaser MJ, Thorsen J, Rasmussen MA, Waage J, Vinding RK, Schoos AMM, Kunæe A, Fink NR, Chawes BL, Bannelykke K, Brejnrod AD, Mortensen MS, Al-Soud WA, Sørensen SJ, Bisgaard H. 2018. Maturation of the gut microbiome and risk of asthma in childhood. Nat Commun 9:141. https://doi.org/10.1038/s41467-018-0077-2.
4. Vatanen T, Kostic AD, d’Hennezel E, Siljander H, Franzosa EA, Yassour M, Kolde R, Vlamakis H, Arthur TD, Hämäläinen A-M, Peet A, Tillmann V, Uibo R, Mokurov S, Dorshakova N, Ionen J, Virtanen SM, Szabo SJ, Porter JA, Lähdesmäki H, Hüttenhöfer C, Gevers D, Obilkevich K, Brejnrod AD, Mortensen MS, Al-Soud WA, Sørensen SJ, Bisgaard H. 2018. Maturation of the gut microbiome and risk of asthma in childhood. Nat Commun 9:141. https://doi.org/10.1038/s41467-018-0077-2.
5. Xavier JB, Young VB, Skufca J, Ginty F, Testerman T, Pearson AT, Macklin P, Mitchell A, Shmulevich I, Xie L, Caporaso JG, Crandall KA, Simone NL, Godoy-Vitorino F, Griffin TJ, Whiteson KL, Gustafson HH, Slade DJ, Schmidt TM, Walther-Antonio MRS, Koren T, Webb-Robertson BJM, Styczynski MP, Johnson WE, Jobin C, Ridlon JM, Koh AY, Yu M, Kelly L, Wargo JA. 2020. The cancer microbiome: distinguishing direct and indirect effects requires a systemic view. Trends Cancer 6:192–204. https://doi.org/10.1016/j.trecanc.2020.01.004.
6. Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpenets TV, Prieto VA, Picente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia D Macedo M, Cotechinhi T, Kumar T, Chen WS, Reddy SM, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Seldburke S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Marcelo Riquelme Sanchez E, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breeman DL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza IC, Huw JW, Patel SP, Woodward SE, Amaria RN, Davies MA, Gershenwald JE, Huw P, Lee JE, Zhang J, Coussens LM, Cooper ZA, Futreal PA, Daniel CR, Ajami NJ, Petrosino JF, Tetzlaff MT, Sharma P, Allinson JP, Jenq RR, Wargo JA. 2018. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359:97–103. https://doi.org/10.1126/science.aam4236.
7. Patel TK, Maitlen K. 2019. The other side of the coin: what beneficial microbes can teach us about pathogenic potential. J Mol Biol 431:2946–2956. https://doi.org/10.1016/j.jmb.2019.05.001.
8. Round JL, Mazmanian SK. 2010. Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc Natl Acad Sci U S A 107:12204–12209. https://doi.org/10.1073/pnas.0909122107.
9. Chow J, Tang H, Mazmanian SK. 2011. Pathobionts of the gastrointestinal microbiota and inflammatory disease. Curr Opin Immunol 23:473–480. https://doi.org/10.1016/j.coi.2011.07.010.
10. Garrett WS, Lord GM, Punj S, Lugo-Villarino G, Mazmanian SKK, Ito S, Glickman JN, Glimcher LH. 2007. Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system. Cell 131:33–45. https://doi.org/10.1016/j.cell.2007.08.017.
11. Taur Y, Coyte K, Schuler J, Robolotti E, Figueroa C, Gjonbalaj M, Littmann ER, Ling L, Miller L, Gyaltshen Y, Fontana E, Morjaria S, Gyurkočka B, Perales MA, Castro-Malaspina H, Tamari R, Ponce D, Kohne G, Barker J, Jakubowiec M, Papadopoulos E, Dahi P, Sauter C, Shaffer B, Young JW, Peled J, Meagher RC, Jenq RR, Van Der Brink MRM, Giralt S, Pamer EG. Xavier JB. 2018. Reconstitution of the gut microbiota of antibiotic-treated patients by autologous fecal microbiota transplant. Sci Transl Med 10: eaap9489. https://doi.org/10.1126/scitranslmed.aap9489.

12. Davar D, Dzutsev AK, McCulloch JA, Rodrigues RR, Chauvin JM, Morrison RM, Deblasio RN, Menna C, Ding Q, Pagliano O, Zidi B, Zhang S, Badger JH, Vetizou M, Cole AM, Fernandes MR, Prescott S, Costa RGF, Balaji AK, Morgun A, Vujkovic-Cvijin I, Wang H, Borhani AA, Schwartz HM, Dubner HM, Ernst SJ, Rose A, Najagin YL, Belkaid Y, Kirkwood JM, Trinchieri G, Zarour HM. 2021. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science 371:955–60. https://doi.org/10.1126/science.abf3363.

13. Robinson CD, Bohannan BJ, Britton RA. 2019. Scales of persistence: transmission and the microbiome. Curr Opin Microbiol 50:42–49. https://doi.org/10.1016/j.mib.2019.09.009.

14. Burns AR, Miller E, Agarwal M, Rolig AS, Milligan-Myhe R, Seredick S, Guillemin K, Bohannan BJ. 2017. Interhost dispersal alters microbiome assembly and can overwhelm host innate immunity in an experimental zebrafish model. Proc Natl Acad Sci U S A 114:11181–11186. https://doi.org/10.1073/pnas.1702511114.

15. Dominguez-Bello MG, Costello EK, Contreras M, Magris M, Hidalgo G, Fierer N, Knight R. 2010. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc Natl Acad Sci U S A 107:11971–11975. https://doi.org/10.1073/pnas.1002601107.

16. Song SJ, Lauber C, Costello EK, Lozupone CA, Humphrey G, Berg-Lyons D, Gregory Caporaso J, Knights D, Clemente JC, Nakielny S, Gordon JL, Fierer N, Knight R. 2013. Coexisting family members share microbiota with one another and with their dogs. Elife 2:e00458. https://doi.org/10.7554/eLife.00458.

17. Brito IL, Gurry T, Zhao S, Huang K, Young SK, Shea TP, Naisilisili W, Jenkins AP, Jupiter SD, Gevers D, Alm EJ. 2019. Transmission of human-associated microbiota along family and social networks. Nat Microbiol 4:964–971. https://doi.org/10.1038/s41564-019-0409-6.

18. Lax S, Sangwan N, Smith D, Larsen P, Handley KM, Richardson M, Guyton JA, Krezalek M, Shogan BD, Defazio J, Flemming I, Shakhsheer B, Weber S, Landon E, Garcia-Houchins S, Siegel J, Alverdy J, Knight R, Stephens B, Gilbert JA. 2017. Bacterial colonization and succession in a newly opened hospital. Sci Transl Med 9:eaaah6500. https://doi.org/10.1126/scitranslmed.aah6500.

19. Danko D, Bezdan D, Afshin EE, Ahsanuddin S, Bhattacharya C, Butler DJ, Chng KR, Donnellan D, Hecht J, Jackson K, Kuchin K, Karasikov M, Lyons A, Mak L, Meleshko D, Mustafa H, Mutai B, Neches RY, Ng A, Nikolayeva O, Nikolayeva T, Png E, Ryan KA, Sanchez JL, Shaaban H, Sierra MA, Thomas D, Young B, Abudayyeh OO, Aickeja A, Bhattacharayya M, Blekman R, Castro-Nallar E, Cañas AM, Chatzieftihimiou AD, Crawford RW, De Filippis F, Deng Y, Desnues C, Dias-Neto E, Dybwad M, Elhai A, Ercolini D, Fierer N, Gankin D, Gootenberg JS, Graf AB, Green DC, Hajjarasouliha I, Hastings JJA, Hernandez M, Irapa G, Jang S, Kahles A, Kelly FJ, Knights K, Kyrpides NC, Labaj PP, Lee KK, Leung M, Ling L, Miller L, Gyaltshen Y, Fontana E, Morjaria S, Gyurkočka B, Perales MA, Castro-Malaspina H, Tamari R, Ponce D, Kohne G, Barker J, Jakubowiec M, Papadopoulos E, Dahi P, Sauter C, Shaffer B, Young JW, Peled J, Meagher RC, Jenq RR, Van Der Brink MRM, Giralt S, Pamer EG, Xavier JB. 2018. Reconstitution of the gut microbiota of antibiotic-treated patients by autologous fecal microbiota transplant. Sci Transl Med 10: eaap9489. https://doi.org/10.1126/scitranslmed.aap9489.

20. Arcilla MS, van Hattem JM, Haverkate MR, Bootma MCJ, van Genderen PJJ, Goorhuis A, Grobusch MP, Lashof AMO, Molhoek N, Schultz C, Stobberingh EE, Verbrugh HA, de Jong MD, Melles DC, Penders J. 2017. Import and spread of extended-spectrum β-lactamase-producing Enterobacteriaceae by international travellers (COMBAT study): a prospective, multicentre cohort study. Lancet Infect Dis 17:78–85. https://doi.org/10.1016/S1473-3099(16)30319-X.

21. Worby CJ, Ear AM, Turbett SE, Becker M, Rao SR, Oliver E, Walker AT, Walters M, Kelly P, Leung DT, Knouse M, Hagmann SH, Ryan ET, Larocque RC. 2020. Acquisition and long-term carriage of multidrug-resistant organisms in US international travelers. Open Forum Infect Dis 7:e1682–e1685. https://doi.org/10.1093/ofid/ofaa543. https://doi.org/10.1093/ofid/ofaaz34. https://doi.org/10.1093/ofid/ofaaz35.

22. Shen Y, Zhou H, Xu J, Wang Y, Zhang Q, Walsh TR, Shao B, Wu C, Hu Y, Yang L, Shen Z, Wu Z, Sun Q, Ou Y, Wang Y, Wang S, Wu Y, Cai C, Li J, Shen J, Zhang R, Wang Y. 2018. Anthropogenic and environmental factors associated with high incidence of mcr-1 carriage in humans across China. Nat Microbiol 3:1054–1062. https://doi.org/10.1038/s41564-018-0205-8.

23. Cabello FC, Godfrey HP, Buschmann AH, Dölz HJ. 2016. Aquaculture as another environmental gateway to the development and globalisation of antimicrobial resistance. Lancet Infect Dis 16:e127–e133. https://doi.org/10.1016/S1473-3099(16)00100-6.

24. Cabello FC, Tomova A, Ivanova L, Godfrey HP. 2017. Aquaculture and mcr colistin resistance determinants. mBio 8:e01229-17. https://doi.org/10.1128/mBio.01229-17.

25. Shen Y, Yin W, Liu D, Shen J, Wang Y. 2018. Reply to Cabello et al., “Aquaculture and mcr colistin resistance determinants.” mBio 9:e01629-18. https://doi.org/10.1128/mBio.01629-18.